Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival

14 Mar 2019

Abstract excerpt

KRAS mutations are among the most common oncogenic events in human carcinomas of endodermal origin, whose presence predicts for resistance to several target therapies [ 1 ]. Conversely, little is known regarding the role and/or clinical impact of KRAS mutations in the setting of the hematological malignancies, including chronic lymphocytic leukemia (CLL), and only in recent years extensive sequencing data have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Chronic Lymphocytic Leukemia Research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30872781
DOI: 10.1038/s41375-019-0444-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survivalPMID 30872781Read ↗

Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review.Semantic proximity Read ↗

Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis.Semantic proximity Read ↗

Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways.Semantic proximity Read ↗

BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance.Semantic proximity Read ↗

Molecular basis of chronic lymphocytic leukemia diagnosis and prognosisSemantic proximity Read ↗

Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade.Semantic proximity Read ↗

Chronic myelomonocytic leukemia with double activating <i>KRAS</i> mutations: molecular characterization of an uncommon caseSemantic proximity Read ↗

ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.Semantic proximity Read ↗

NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL.Semantic proximity Read ↗

Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a differenceSemantic proximity Read ↗

IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomesSemantic proximity Read ↗

Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.